Pharma.Aerowelcomes the global transport and logistics provider DSV as full member and the pharma supply chain risk management platform Mytigateas associate partner.The international cross-industry collaboration platform now comprises of 46 members and associate partners from LifeScience and MedTech shippers, IATA CEIV certified cargo communities, airport operators and other air cargo industry stakeholders. Frank Van Gelder, secretary general of Pharma.Aero, said: “Pharma.Aero is happy to welcome DSV to its global membership network. Increasing our membership with strong global players with a dedicated life science focus will benefit to the air transportation and handling of pharmaceutical and vaccine shipments. Global collaboration and sharing of expertise are pivotal within the air cargo industry to further increase the reliable transport.
“In addition to DSV, we welcome Mytigate as one of our associate partners. This will further spread the technology insights and solutions supporting traceability, visibility, and transparency of the end-to-end pharma supply chain.
“Both companies showed immediate dedication and input to the second International Masterclass on Pharma Logistics in Abu Dhabi from 5 to 9 of September, being part of the program and sponsorship.”Eric ten Kate, vice president, global vertical lead healthcare, DSV, said: “We are excited to be joining Pharma.Aero as a Full Member. The platform allows us to collaborate with the different stakeholders in the pharma supply chain and contribute to the overall mission to improve the quality of pharma transportation. it is a privilege to be part of a global community working toward raising the standards and defining solutions across multiple pharma-related fields and business markets. This aligns with DSV’s global healthcare strategy to ultimately assure patient safety at all times.” Yvonne Ziegler, CEO Mytigate GmbH, added: “Mytigate feels honoured to join Pharma.Aero as an Associate Partner and looks forward to contributing to its mission to improve the quality of pharma transportation.”